Selective Enhancement of Swine Myocardium with a Novel Ultrasound Enhancing Agent During Transthoracic Echocardiography.
Michael CimorelliMichael A FlynnBrett AngelEmily ReimoldSahil S BankaBenjamin AndrienAaron FafarmanRichard HunekeAndrew KohutSteven WrennPublished in: Journal of cardiovascular translational research (2022)
Ultrasound enhancing agents are approved to delineate the endocardial border and opacify the left ventricle cavity (LVC). We present a nested phase change agent (NPCA) designed to enable selective myocardial enhancement without enhancing the LVC by employing a dual-activation mechanism dependent on sufficient ultrasound intensity and the microenvironment of the myocardium. Swine received bolus injections of NPCA while echocardiograms were collected and processed to determine background-subtracted acoustic intensities (AI) in the LVC and septal myocardium. At mechanical index (MI) ≥ 0.8, the NPCA enhanced the myocardium selectively (p < 0.001) while the LVC remained at baseline AI. A 5-mL bolus of NPCA enhanced swine myocardium and enhancement persisted for > 5 min at 1.4 MI, while hemodynamics and EKG remained normal. Our findings demonstrate that the NPCA enhances swine myocardium selectively without enhancing the LVC. The NPCA could have utility for functional and structural echocardiographic studies with clinical ultrasound using standard settings.
Keyphrases
- magnetic resonance imaging
- left ventricular
- ultrasound guided
- pulmonary hypertension
- stem cells
- artificial intelligence
- computed tomography
- contrast enhanced ultrasound
- case control
- heart failure
- coronary artery
- high intensity
- deep learning
- ejection fraction
- platelet rich plasma
- left atrial
- cardiac resynchronization therapy